Artificial vascular system

Grader A: partial

The first engineered human vessel (Humacyte Symvess) was FDA-approved Dec 2024 and launched 2025, after humanitarian use in Ukraine; use is a tiny share of vascular procedures. Real use within 5 years of 2020, below 5%.

Test: D37 health: share of relevant patients, providers or procedures using it by 2022 (hit >=5%; partial <5% real use by 2022 or 5% in 2023-2025; miss no real use by 2025); relevant: vascular repair/bypass procedures

• Humacyte Announces FDA Approval of SYMVESS (2024-12-20): First acellular tissue engineered vessel approved for extremity vascular trauma

Grader B: partial

The first tissue-engineered vessel (Humacyte Symvess) was FDA-approved in Dec 2024 for extremity vascular trauma, inside the 5-year window. Use in 2025 is niche (one indication, early launch). Conventional synthetic Dacron/ePTFE grafts predate the poster and are not what the label means.

Test: D37 health: >=5% of vascular grafting procedures use engineered vessels by 2022 = hit; real use below 5% or 5% in 2023-2025 = partial; no real use by 2025 = miss.

• FDA Approves First Acellular Tissue Engineered Vessel to Treat Vascular Trauma in Extremities (2024-12-20): First approval of a tissue-engineered vessel, late 2024; no earlier routine use.